Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, People's Republic of China.
Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, 430022, People's Republic of China.
Drug Des Devel Ther. 2021 May 20;15:2151-2159. doi: 10.2147/DDDT.S305792. eCollection 2021.
Although temozolomide has been extensively used to treat various tumors, there is a lack of large-cohort studies on temozolomide's toxicity profile. The toxicity profiles and associated factors in patients treated with temozolomide-containing regimens were analyzed.
Patients treated with temozolomide-containing regimens in the Affiliated Union Hospital of Huazhong University of Science and Technology from January 2008 to December 2019 were included. A retrospective analysis of the clinical data of patients treated with temozolomide-containing regimens was performed. Univariate chi-square test and multivariate logistic regression analysis were employed to identify factors associated with the occurrence of toxicities.
Among the 1057 patients received temozolomide-containing regimens, 922 patients were included in our analyses. Of the 922 patients, 484 patients (52.5%) experienced toxicities. Univariate analysis revealed that radiotherapy, chemotherapy cycle, chemotherapy regimen, and clinical stage were significantly associated with the toxicity during temozolomide treatment ( < 0.05). The chemotherapy regimen, chemotherapy cycle, and clinical stage were significantly associated with the overall occurrence of toxicities ( < 0.05). A chemotherapy regimen, chemotherapy cycle, and clinical stage were associated with the hematological system's toxicities, whereas gender, age, clinical diagnosis, and clinical stage were related to gastrointestinal toxicities ( < 0.05). Clinical diagnosis, chemotherapy regimen, and age were associated with liver toxicity ( < 0.05).
Toxicities are common among patients receiving temozolomide-containing regimens. Clinicians should be aware of factors associated with toxicities to minimize the impact of the toxicity.
替莫唑胺已广泛用于治疗各种肿瘤，但关于其毒性谱的大样本研究较少。本研究旨在分析接受替莫唑胺方案治疗患者的毒性谱及相关因素。
回顾性分析 2008 年 1 月至 2019 年 12 月在华中科技大学同济医学院附属协和医院接受替莫唑胺方案治疗的患者的临床资料，采用单因素 χ2 检验和多因素 logistic 回归分析方法，筛选与毒性发生相关的因素。
共纳入 1057 例接受替莫唑胺方案治疗的患者，其中 922 例纳入本研究。922 例患者中，484 例（52.5%）出现毒性反应。单因素分析显示，放疗、化疗周期、化疗方案和临床分期与替莫唑胺治疗期间的毒性显著相关（<0.05）。化疗方案、化疗周期和临床分期与毒性的总发生率显著相关（<0.05）。化疗方案、化疗周期和临床分期与血液系统毒性相关，而性别、年龄、临床诊断和临床分期与胃肠道毒性相关（<0.05）。临床诊断、化疗方案和年龄与肝毒性相关（<0.05）。
接受替莫唑胺方案治疗的患者常见毒性反应，临床医生应了解与毒性相关的因素，以尽量减少毒性的影响。
